Primecap Management Co. CA Sells 3,400 Shares of Repligen Co. (NASDAQ:RGEN)

Primecap Management Co. CA reduced its stake in shares of Repligen Co. (NASDAQ:RGEN) by 5.8% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 54,729 shares of the biotechnology company’s stock after selling 3,400 shares during the quarter. Primecap Management Co. CA owned about 0.10% of Repligen worth $6,899,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in RGEN. Norges Bank purchased a new stake in Repligen during the 4th quarter valued at $48,208,000. Bank of New York Mellon Corp raised its stake in shares of Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after acquiring an additional 237,884 shares during the period. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 26.7% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 39.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock worth $54,149,000 after purchasing an additional 121,305 shares during the period. Finally, Public Employees Retirement Association of Colorado grew its holdings in Repligen by 448.0% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 112,863 shares of the biotechnology company’s stock valued at $20,293,000 after purchasing an additional 92,268 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Stock Performance

RGEN stock opened at $142.03 on Thursday. Repligen Co. has a 1-year low of $110.45 and a 1-year high of $211.13. The business has a 50-day moving average price of $146.57 and a 200 day moving average price of $155.94. The company has a market capitalization of $7.94 billion, a P/E ratio of 568.12, a PEG ratio of 4.20 and a beta of 0.94. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The business had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. During the same quarter in the previous year, the business posted $0.53 EPS. The company’s quarterly revenue was down 3.2% compared to the same quarter last year. As a group, equities research analysts forecast that Repligen Co. will post 1.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RGEN. Guggenheim began coverage on shares of Repligen in a research note on Tuesday, June 18th. They issued a “neutral” rating for the company. JPMorgan Chase & Co. raised their price target on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a research report on Tuesday, July 30th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price for the company. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $190.00 price target on shares of Repligen in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $188.38.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the transaction, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.